Companies › Novaliq
1 active drug program in 26 registered trials: 12 Phase 2, 10 Phase 4, 3 Phase 1, 1 Phase 3; Neurology, Cardiovascular, Gastroenterology, Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tacrolimus (NOV05) FK506-binding protein 1A inhibitor | FKBP1A | Phase 2 | Non-infectious Anterior Uveitis; Kidney Transplantation; Kidney Disease, End-Stage; Renal Transplant Recipients … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03266393 | Tacrolimus (NOV05) | Phase 4 | Kidney Transplantation | Genitourinary | Mar 2023 |
| NCT04665310 | Tacrolimus (NOV05) | Phase 4 | Kidney Disease, End-Stage | Genitourinary | Jul 2025 |
| NCT07285070 | Tacrolimus (NOV05) | Phase 2 | Non-infectious Anterior Uveitis | Infectious disease | Oct 2026 |
| NCT03797196 | Tacrolimus (NOV05) | Phase 4 | Renal Transplant Recipients | Genitourinary | Dec 2026 |
| NCT03841097 | Tacrolimus (NOV05) | Phase 4 | Kidney Transplant; Complications | Genitourinary | Dec 2026 |
| NCT05242315 | Tacrolimus (NOV05) | Phase 4 | Liver Transplant; Complications | Cardiovascular | Dec 2026 |
| NCT05089604 | Tacrolimus (NOV05) | Phase 4 | Liver Transplantation | Other | Dec 2026 |
| NCT06701825 | Tacrolimus (NOV05) | Phase 4 | Kidney Disease, Chronic | Genitourinary | Dec 2026 |
| NCT01804634 | Tacrolimus (NOV05) | Phase 2 | Refractory and/or Relapsed Metastatic Solid Tumors | Oncology | Jan 2027 |
| NCT05621759 | Tacrolimus (NOV05) | Phase 2 | Graft Vs Host Disease | Immunology | Jan 2027 |
| NCT03321656 | Tacrolimus (NOV05) | Phase 2 | End Stage Renal Disease | Genitourinary | Mar 2027 |
| NCT06751992 | Tacrolimus (NOV05) | Phase 4 | Kidney Transplant Recipients | Genitourinary | May 2027 |
| NCT06828796 | Tacrolimus (NOV05) | Phase 2 | Hematologic Disease and Disorders | Hematology | Jun 2027 |
| NCT06529536 | Tacrolimus (NOV05) | Phase 4 | Solid Organ Transplant | Other | Aug 2027 |
| NCT03816332 | Tacrolimus (NOV05) | Phase 1 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Oncology | Sep 2027 |
| NCT06807606 | Tacrolimus (NOV05) | Phase 2 | Hematologic Malignancies | Oncology | Nov 2027 |
| NCT03769298 | Tacrolimus (NOV05) | Phase 2 | Kidney Pancreas Transplantation | Gastroenterology | Dec 2027 |
| NCT06591884 | Tacrolimus (NOV05) | Phase 1 | Oral Erosive Lichen Planus | Immunology | Dec 2027 |
| NCT07302776 | Tacrolimus (NOV05) | Phase 1 | GVHD | Oncology | Feb 2028 |
| NCT00882895 | Tacrolimus (NOV05) | Phase 2 | Lymphoma, Non-Hodgkin | Oncology | Jun 2028 |
| NCT06235892 | Tacrolimus (NOV05) | Phase 3 | Organ Grafts | Other | Jun 2028 |
| NCT06268769 | Tacrolimus (NOV05) | Phase 4 | Immunosuppression | Other | Nov 2028 |
| NCT03970096 | Tacrolimus (NOV05) | Phase 2 | Acute Leukemia | Oncology | Dec 2028 |
| NCT04302870 | Tacrolimus (NOV05) | Phase 2 | Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Neurology | Dec 2030 |
| NCT05027945 | Tacrolimus (NOV05) | Phase 2 | Immunodeficiency | Hematology | Jul 2031 |
| NCT05031897 | Tacrolimus (NOV05) | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | Apr 2032 |
Aadi Bioscience Mercator MedSystems Ascension Health F2G Rapamycin Holdings
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.